These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Antonopoulos AS; Margaritis M; Lee R; Channon K; Antoniades C Curr Pharm Des; 2012; 18(11):1519-30. PubMed ID: 22364136 [TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of statins and related pharmacological experimental approaches. Alegret M; Silvestre JS Timely Top Med Cardiovasc Dis; 2007 Apr; 11():E10. PubMed ID: 17473899 [TBL] [Abstract][Full Text] [Related]
16. Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease. Adam O; Laufs U Antioxid Redox Signal; 2014 Mar; 20(8):1238-50. PubMed ID: 23919665 [TBL] [Abstract][Full Text] [Related]
17. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Krysiak R; Okopień B; Herman Z Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488 [TBL] [Abstract][Full Text] [Related]
18. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Wierzbicki AS; Viljoen A Drug Saf; 2010 Feb; 33(2):115-25. PubMed ID: 20082538 [TBL] [Abstract][Full Text] [Related]
19. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease. Erez G; Leitersdorf E Eur J Vasc Endovasc Surg; 2007 Feb; 33(2):192-201. PubMed ID: 17185010 [TBL] [Abstract][Full Text] [Related]
20. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]